Crossmark

Immunohistochemistry scoring for human epidermal growth factor receptor 2 can be used to predict pathological response to cisplatin-based neoadjuvant chemotherapy in a subset of immunohistochemically subtyped muscle-invasive bladder cancer

Crossref DOI link: https://doi.org/10.1007/s00428-025-04196-1

Published Online: 2025-07-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saka, Manduwa

Teramoto, Yuki

Haga, Hironori
License Information

Text and Data Mining valid from 2025-07-24

Version of Record valid from 2025-07-24
More Information

Article History

Received: 4 May 2025

Revised: 2 July 2025

Accepted: 14 July 2025

First Online: 24 July 2025

Declarations

:

: The authors have no competing interests to declare that are relevant to the content of this article.

Document is current

Any future updates will be listed below